2 results
Approved WMOCompleted
The objective of this crossover study and randomized controlled trial is to compare ΔP levels during INTELLiVENT®-ASV with conventional lung protective ventilation in patients with moderate or severe ARDS.
Approved WMOPending
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.